SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (450)5/20/1999 9:59:00 AM
From: ouija  Read Replies (1) of 717
 
It appears pretty clear to me. PARTEQ (Queens University) has the use patents tied up in the US and some other countries, but not all. In the countries not covered, other people can develop ALA products. But DUSA has exclusive control in this country (plus) under PARTEQ's use patents. Also, DUSA has patents on their specific approach. Since this is a device/drug combination, once the original patent runs out, DUSA still has generics blocked unless they go the same trial path which DUSA followed, a large barrier to entry not available with just drugs.

What does Waxman-Hutch refer to?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News